Cornerstone Capital Management Holdings LLC. bought a new position in Global Blood Therapeutics Inc (NASDAQ:GBT) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 19,900 shares of the company’s stock, valued at approximately $616,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank of America Corp DE boosted its position in shares of Global Blood Therapeutics by 103.6% in the first quarter. Bank of America Corp DE now owns 7,141 shares of the company’s stock valued at $263,000 after acquiring an additional 3,633 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Global Blood Therapeutics by 53.0% in the second quarter. Russell Investments Group Ltd. now owns 44,014 shares of the company’s stock valued at $1,203,000 after acquiring an additional 15,253 shares during the period. Schwab Charles Investment Management Inc. boosted its position in shares of Global Blood Therapeutics by 35.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 149,634 shares of the company’s stock valued at $4,093,000 after acquiring an additional 38,829 shares during the period. DekaBank Deutsche Girozentrale bought a new position in shares of Global Blood Therapeutics in the second quarter valued at approximately $211,000. Finally, Rhumbline Advisers boosted its position in shares of Global Blood Therapeutics by 118.5% in the second quarter. Rhumbline Advisers now owns 41,801 shares of the company’s stock valued at $1,143,000 after acquiring an additional 22,670 shares during the period. Hedge funds and other institutional investors own 90.25% of the company’s stock.

Global Blood Therapeutics Inc (NASDAQ GBT) opened at $39.80 on Tuesday. The company has a market cap of $1,800.00 and a P/E ratio of -15.61. Global Blood Therapeutics Inc has a one year low of $13.35 and a one year high of $45.85.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same period in the previous year, the firm earned ($0.58) EPS. analysts anticipate that Global Blood Therapeutics Inc will post -2.54 EPS for the current fiscal year.

In related news, insider Jung Choi sold 3,000 shares of Global Blood Therapeutics stock in a transaction on Friday, September 29th. The shares were sold at an average price of $30.00, for a total value of $90,000.00. Following the transaction, the insider now directly owns 140,055 shares of the company’s stock, valued at $4,201,650. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Perceptive Advisors Llc bought 175,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 19th. The stock was purchased at an average cost of $38.00 per share, for a total transaction of $6,650,000.00. The disclosure for this purchase can be found here. Insiders have sold 91,500 shares of company stock worth $3,113,000 over the last three months. Insiders own 5.30% of the company’s stock.

GBT has been the subject of several research analyst reports. Cowen reiterated a “buy” rating and set a $83.00 target price on shares of Global Blood Therapeutics in a research report on Thursday, November 9th. Wedbush reiterated an “ourperform” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a research report on Monday, September 18th. Zacks Investment Research upgraded shares of Global Blood Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Oppenheimer set a $53.00 target price on shares of Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, November 13th. Finally, ValuEngine lowered shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $62.07.

WARNING: This story was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://theolympiareport.com/2017/12/26/cornerstone-capital-management-holdings-llc-takes-position-in-global-blood-therapeutics-inc-gbt.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.